Stuttgart - Delayed Quote EUR

IDEAYA Biosciences, Inc. (30J.SG)

23.20

+0.80

+(3.57%)

At close: January 31 at 9:34:14 PM GMT+1

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 30, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan

PR Newswire 16 hours ago

IDYA
Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where IDEAYA Biosciences, Inc. (NASDAQ:IDYA) stands against the other stocks. The Fed’s Probable Path and its Impact on Earnings A lot is happening in the market, especially within the growth sectors. […]

Insider Monkey yesterday

IDYA
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.

PR Newswire 4 days ago

IDYA
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 days ago

IDYA
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates.

PR Newswire 19 days ago

IDYA
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences (IDYA) said Sunday it has entered into an exclusive licensing agreement with Jian

PREMIUM
MT Newswires last month

600276.SS

IDYA
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, SHA: 600276), an innovative global pharmaceutical company headquartered in China focused on unmet clinical needs. Under the terms of the agreement, IDEAYA wil

PR Newswire last month

IDYA

600276.SS
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the Independent Data Monitoring Committee (IDMC) recommendation of a move-forward dose and the completion of the Part 2a dose optimization consistent with the U.S. Food and Drug Administration's (FDA) Project Optimus guidelines for the potential registration-enabling Phase 2/3 trial evaluating the combination of darovasertib and crizo

PR Newswire last month

IDYA
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the development candidate nomination of IDE251, a potential first-in-class KAT6/7 dual inhibitor.

PR Newswire last month

IDYA
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

It hasn't been the best quarter for IDEAYA Biosciences, Inc. ( NASDAQ:IDYA ) shareholders, since the share price has...

Simply Wall St. last month

IDYA
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its virtual Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 16, 2024 at 8:00 am to 9:30 am ET.

PR Newswire last month

IDYA
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has dosed the first patient in the IDEAYA-sponsored Phase 1 trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pem

PR Newswire last month

IDYA
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced development candidate nomination of IDE892, a potential best-in-class MTA-cooperative PMRT5 inhibitor.

PR Newswire last month

IDYA
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations events.

PR Newswire last month

IDYA
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Ideaya Biosciences Inc. (NASDAQ:IDYA) stands against the other NASDAQ stocks. Potomac Wealth Advisors president Mark Avallone joined CNBC’s ‘The Exchange’ on November 16 to discuss where he […]

Insider Monkey 2 months ago

IDYA
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

PR Newswire 2 months ago

IDYA
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2024.

PR Newswire 2 months ago

IDYA
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

BEIJING & SOUTH SAN FRANCISCO, Calif., November 11, 2024--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exercised the option for an exclusive worldwide license for Biocytogen's B7H3/PTK7 BsADC program, IDE034, and has

Business Wire 2 months ago

IDYA
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the selection of IDE034, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, as a development candidate and the exercise of its option for an exclusive worldwide license from Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) for potential first-in-class B7H3/PTK7 BsADC program.

PR Newswire 2 months ago

2315.HK

IDYA
Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

The consensus price target hints at an 81.9% upside potential for IDEAYA Biosciences (IDYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 2 months ago

IDYA

Performance Overview

Return	30J.SG	S&P 500
YTD	-0.85%	+2.26%
1-Year	-41.71%	+22.65%
3-Year	+75.76%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IDEAYA Biosciences, Inc. (30J.SG)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events

Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

Performance Overview